Oligonucleotides for the inhibition of human eg5 expression
AssigneeAventis Pharma Deutschland GmbH
InventorsEugen Uhlmann, Beate Greiner, Eberhard Unger, Gislinde Gothe, Marc Schwerdel
Life of this patent
Estimating the term…
Abstract
The present invention relates to an oligonucleotide or a derivative thereof which has a sequence that corresponds to a particular fragment of a nucleic acid sequence which encodes human eg5 or a mutant form thereof; the invention further relates to a method of making the oligonucleotide and the use thereof.
Claims12
An oligonucleotide or a derivative thereof, comprising up to 100 nucleotides, wherein the sequence of the oligonucleotide or derivative thereof comprises at least one of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO;5, SEQ ID NO:6, SEQ ID NO:7. SEQ ID NO:8, or SEQ ID NO:9.
Dependencies are inferred from the claim text.